Drug Profile


Alternative Names: BL 191; Claudicat; Dospan Pento; Elorgan; Oxpentifylline; Pentoxifilina; Trental

Latest Information Update: 22 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Anticoagulants; Antithrombotics; Small molecules; Vascular disorder therapies; Vasodilators; Xanthines
  • Mechanism of Action Cytokine inhibitors; Immunosuppressants; Phosphoric diester hydrolase inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Intermittent claudication; Tinnitus
  • Discontinued HIV-1 infections; Kaposi's sarcoma; Lung disorders; Transplant rejection

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 Aug 2004 No development reported - Clinical-Phase-Unknown for Kaposi's sarcoma in USA (PO)
  • 27 Aug 2004 No development reported - Preclinical for HIV-1 infections in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top